Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • renuka22
    Member
    • Mar 2017
    • 22

    #1

    RNA seq bioinformatics

    Hello all,

    I have RNA seq data from 2 replicates of control and treated (say for example C1,C2,T1,T2). But when I compared the replicates separately (C1vsT1) ,(C2vsT2) there were around 1500 differentially expressed genes, but when the company combined the replicates together (all control C1C2 together vs T1T2 together) the differentially expressed genes were around 160 only. Also, the differentially expressed genes which showed up for combined replicates were different than the ones in C1TI or C2T2. Could anyone tell me what might be the reason for this?

    Thanks
  • Biocomputronics
    Junior Member
    • Sep 2017
    • 6

    #2
    It all depends on how you are doing the test for differential gene expression. But the basic idea is around statistical power and significance. Generally speaking, you cannot compare one replicate for treatment A with one replicate for treatment B since you have zero statistical power. Even 2 replicates is generally considered not enough since there is a lot of biological and technical variation involved. Most people suggest at least 3 replicates per condition. Then you need to use a principled statistical method to determine differential expression such as the one's incorporated in the packages edgeR or DESeq2. You can't really use simplistic tests like a t-test with RNA-seq data.

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
      by SEQadmin2



      CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

      Despite this, “CRISPR helped turn genome editing from a specialized technique into
      ...
      Today, 11:01 AM
    • SEQadmin2
      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM
    • SEQadmin2
      Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
      by SEQadmin2



      Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
      ...
      07-09-2026, 11:10 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, Today, 02:55 AM
    0 responses
    6 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-24-2026, 12:17 PM
    0 responses
    11 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-23-2026, 11:41 AM
    0 responses
    12 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-20-2026, 11:10 AM
    0 responses
    24 views
    0 reactions
    Last Post SEQadmin2  
    Working...